Markus Riederer - Idorsia VP Biology

IDIA Stock  CHF 1.07  0.20  22.99%   

Insider

Markus Riederer is VP Biology of Idorsia
Age 61
Phone41 58 844 10 10
Webhttps://www.idorsia.com

Idorsia Management Efficiency

The company has return on total asset (ROA) of (0.4196) % which means that it has lost $0.4196 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (64.6068) %, meaning that it generated substantial loss on money invested by shareholders. Idorsia's management efficiency ratios could be used to measure how well Idorsia manages its routine affairs as well as how well it operates its assets and liabilities.
Idorsia has accumulated 1.13 B in total debt with debt to equity ratio (D/E) of 112.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Idorsia has a current ratio of 7.42, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Idorsia until it has trouble settling it off, either with new capital or with free cash flow. So, Idorsia's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Idorsia sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Idorsia to invest in growth at high rates of return. When we think about Idorsia's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Lutz WevelsiepBasilea Pharmaceutica AG
N/A
Ursula EberhardtBasilea Pharmaceutica AG
61
Fabian ChiozzaVAT Group AG
42
Jennifer ClancyLonza Group AG
N/A
Constance WardLonza Group AG
N/A
Maria NunezLonza Group AG
N/A
Laurenz KellenbergerBasilea Pharmaceutica AG
56
Dirk OehlersLonza Group AG
N/A
David VeitchBasilea Pharmaceutica AG
58
Peer SchroderBasilea Pharmaceutica AG
N/A
Andreas BohrerLonza Group AG
N/A
Adesh KaulBasilea Pharmaceutica AG
49
KokKien LohStraumann Holding AG
56
Camila FinziStraumann Holding AG
51
K DahlstroemVAT Group AG
N/A
J ZollerVAT Group AG
N/A
Wolfgang BeckerStraumann Holding AG
57
Sanna FowlerLonza Group AG
N/A
J HaggertyVAT Group AG
N/A
Peter HackelStraumann Holding AG
54
V ValentinVAT Group AG
N/A
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland. Idorsia Ltd is traded on Switzerland Exchange in Switzerland. Idorsia (IDIA) is traded on SIX Swiss Exchange in Switzerland and employs 11 people.

Management Performance

Idorsia Leadership Team

Elected by the shareholders, the Idorsia's board of directors comprises two types of representatives: Idorsia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Idorsia. The board's role is to monitor Idorsia's management team and ensure that shareholders' interests are well served. Idorsia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Idorsia's outside directors are responsible for providing unbiased perspectives on the board's policies.
Simon Jose, Ex Officer
Andrew Weiss, Sr Communications
Olivier Lambert, Sr Assurance
Christoph Boss, VP Chemistry
Martine Clozel, Ex Officer
JeanPaul MD, CEO Director
Alexander Khatuntsev, VP HR
Andr Muller, Ex CFO
Julien LLM, Group VP
Guy MD, Ex Officer
Markus Riederer, VP Biology

Idorsia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Idorsia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Idorsia Stock Analysis

When running Idorsia's price analysis, check to measure Idorsia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Idorsia is operating at the current time. Most of Idorsia's value examination focuses on studying past and present price action to predict the probability of Idorsia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Idorsia's price. Additionally, you may evaluate how the addition of Idorsia to your portfolios can decrease your overall portfolio volatility.